Skip to main content

Immunomodulatory effect of extracorporeal photopheresis after successful treatment of resistant renal allograft rejection

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Background:

Acute renal allograft rejection contributes to patient morbidity. Standard immunosuppressives are only partially effective and have significant side effects. Extracorporeal photopheresis (ECP) has been effective in reversing the acute rejection process. T cell cytokine expression is implicated in rejection and tolerance but actual changes in the cytokine profile of ECP-treated individuals have not been documented. Methods:

ECP was administered to a patient with acute renal allograft rejection resistant to other immunosuppressives. Enzyme-linked immunosorbent spot (ELISPOT) assay was performed to determine the frequency of mitogen-induced cytokine-producing cells before and after ECP. Results:

ECP resulted in resolution of rejection; serum creatinine concentration fell from 7.1 to 2.2 mg/dl; ELISPOT revealed a three-fold increase in the frequency of IL-5 producing cells; IFN-γ:IL-5 ratio shifted from 2.73 pre-treatment to 1.01 post-treatment. Conclusion:

Effective therapy of acute allograft rejection with ECP alters the peripheral blood cytokine profile towards “type 2” cytokines, suggesting that alteration of T cell cytokine profiles may contribute to the resolution of the process.

Keywords: ELISPOT assay; allograft rejection; photopheresis

Document Type: Short Communication

DOI: http://dx.doi.org/10.1034/j.1600-0781.2001.017002079.x

Affiliations: 1: Department of Dermatology and 2: Nephrology Division, Department of Medicine and Departments of 3: Surgery and 4: Institute of Pathology, Case Western Reserve University;

Publication date: April 1, 2001

mksg/ppp/2001/00000017/00000002/art00006
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more